SEC Form 4 · accession 0001209191-15-024720
INCYTE CORP · INCY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard S Levy
Officer — EVP, Chief Drug Dev Officer
Period of report
Mar 6, 2015
Accepted (ET)
Mar 10, 2015 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000879169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 6, 2015 | M | 25,000 | $18.32 | A | 46,227 | D | |
| Common StockF1,F2,F3 | Mar 6, 2015 | S | 25,000 | $89.91 | D | 21,227 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F4 | $18.32 | Mar 6, 2015 | M | 25,000 | D | — | Feb 8, 2020 | Common Stock | 25,000 | 66,782 | D |
Explanation of responses
- F1Represents weighted average sale price. Actual sale prices ranged from $89.00 - $91.75.
- F2Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
- F3This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
- F4Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.